Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2019

Primary Completion Date

May 27, 2021

Study Completion Date

December 31, 2025

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Concurrent chemotherapy and KN026

30 mg/kg Q3W KN026 75 mg/m2 docetaxol

DRUG

KN026 monotherapy

30 mg/kg Q3W KN026

DRUG

KN026 combination

30 mg/kg Q3W KN026 5 mg/kg Q3W KN046

Trial Locations (1)

Harbin Medical University Cancer Hospital, Harbin

All Listed Sponsors

lead

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

INDUSTRY